Patent · US Active

Targeted replacement of endogenous T cell receptors

US12398193B2 · kind B2 · utility

0Cited by
12References
22Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJan 27, 2023
Grant dateAug 26, 2025
Priority date
Expiry dateSep 29, 2043

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K14/7051
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Provided herein are methods and compositions for editing the genome of a human T cell. In some embodiments, a heterologous T cell receptor (TCR)-β chain and a heterologous TCR-α chain are inserted into exon 1 of a TCR subunit constant gene in the genome of the T cell.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.